What it sells
End-to-end workspace to accelerate scientific discovery
Business model breakdown
Buyer: who owns the budget?
Individual researchers and grad students; lab leads; university libraries (site license); pharma/HEOR teams.
Trigger: what makes them buy now?
Manual literature screening takes weeks and generic AI gives unreliable citations.
Workflow: what inputs become what output?
Search 300M+ papers, screen and verify citations, run PRISMA systematic reviews, meta-analysis, and draft manuscripts in one workspace.
Economics: what it saves and how it charges
Freemium SaaS with per-seat subscriptions and institutional site licenses.
Distribution: how it reaches customers
Self-serve signup with free tier, referral program, enterprise/site licence sales.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Fall 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.